Janssen faces fresh claim over cancer drug royalties

A Danish biotech company has renewed its dispute with Belgium’s Janssen Pharmaceuticals, claiming US$405 million over a blood cancer treatment just weeks after a tribunal dismissed an earlier arbitration concerning the same licensing agreement.

Get unlimited access to all Global Arbitration Review content